Tumor Necrosis Factor Inhibitors for Inflammatory Bowel Disease | New England Journal of
Medicine Skip to main content The New England Journal of Medicine homepage Advanced …

Crohn's disease and ulcerative colitis are two idiopathic inflammatory disorders of the GI
tract. Manifestations of disease can be severe and lead to long term therapy with a variety of …

Ulcerative colitis (UC) and Crohn's disease (CD) are part of Inflammatory Bowel Diseases
(IBD) and have pathophysiological processes such as bowel necrosis and enteric neurons …

Crohn's disease is a T helper type 1 response immune disease characterized by increased
production of interleukin-12 tumor necrosis factor-a (TNF-a), and interferon-g. Clinical trials …

Biological treatment with tumor necrosis factor (TNF) inhibitors is successful in the
management of inflammatory bowel disease (IBD). All TNF inhibitors antagonize the pro …

Tumor necrosis factor‐α (TNFα), a proinflammatory cytokine, plays an important role in the
pathogenesis of inflammatory bowel disease (IBD). Biotechnology agents including a …

OBJECTIVES: Tumor necrosis factor-α (TNF-α) is an important cytokine involved in the
pathogenesis of inflammatory bowel disease. The monoclonal antibody to TNF-α, infliximab …

Anti-tumour necrosis factor-alpha (TNF-a) agents have changed the way of treating
inflammatory bowel diseases (IBD) refractory to conventional medications (corticosteroids …

Abstract Background and Aim: Anti‐tumor‐necrosis‐factor‐alpha (anti‐TNF‐α) medications
are effective in inflammatory bowel disease (IBD), but have an increased risk of tuberculosis …

Inflammatory bowel disease (IBD), in particular Crohn's disease refractory to conventional
therapy, fistulizing Crohn's disease and chronic active ulcerative colitis, generally respond …